stem cell transplantation for rheumatic autoimmune diseases风湿免疫性疾病的干细胞移植.pdfVIP

Available online /content/10/5/217 Review Stem cell transplantation for rheumatic autoimmune diseases Thomas Hügle1 and Jacob M van Laar2 1Department of Rheumatology, University of Basel, Felix Platter Spital, Burgfelderstrasse 101, 4012 Basel, Switzerland 2Musculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK Corresponding author: Jacob M van Laar, j.m.van-laar@ncl.ac.uk Published: 10 October 2008 Arthritis Research Therapy 2008, 10:217 (doi:10.1186/ar2486) This article is online at /content/10/5/217 © 2008 BioMed Central Ltd Abstract multistep treatment modality (Figure 1) followed clinical Immunoablative therapy and hematopoietic stem cell trans- observations of remissions of AD in patients who were trans- plantation (HSCT) is an intensive treatment modality aimed at planted for concomitant hemato-oncological conditions [5]. ‘resetting’ the dysregulated immune system of a patient with The immunological principles were subsequently confirmed immunoablative therapy and allow outgrowth of a nonautogressive through mechanistic studies in animal models of AD [6]. immune system from reinfused hematopoietic stem cells, either HSCT in AD was widely pioneered in the 1990s at a time from the patient (autologous HSCT) or a healthy donor (allogeneic when few biologicals were available to treat AD and when HSCT). HSCT has been shown to